Belgium
Precirix, founded in 2014 and headquartered in Belgium, is a clinical-stage biotechnology company committed to enhancing cancer patient care through innovative precision radiopharmaceuticals. The company's technology leverages camelid single domain antibody fragments to develop targeted therapies.
Its flagship product, CAM-H2, is advancing through a Phase I/II clinical trial aimed at treating HER2-positive tumors. The product exemplifies PRECIRIX's unique theranostic model, utilizing the same molecular structure for both patient diagnosis via imaging and subsequent therapy.
In its latest financial milestone, PRECIRIX secured a substantial €80.00M Series B investment as of 01 March 2022. This funding round was led by notable investors, including Novo Holdings, Pontifax, HealthCap, GIMV, BioMed Partners, Jeito Capital, V-Bio Ventures, Inkef, and Forbion Capital Partners, signaling strong confidence in its growth trajectory. This backing further solidifies PRECIRIX's position in the competitive oncology space, poised for significant advancements in radiopharmaceutical development.
